In April, the retail sales volume of 13,020 units, NIO's all-new ES8 has won the sales champion of large SUVs for five consecutive months.
The all-new NIO ES8 has won the large SUV sales champion for five consecutive months.
Recently, the China Automobile Dealers Association's passenger car market information joint branch released the latest market data. In April 2026, the new ES8 from NIO had a retail sales volume of 13,020 units, winning the top spot in the large SUV category and in the market for vehicles priced above 400,000 yuan for five consecutive months. With its phenomenal market performance, the new ES8 has further solidified its leading position in the high-end pure electric SUV market.
As of now, the new ES8 has already attracted over 100,000 users and achieved the milestone of delivering 100,000 new vehicles in just 215 days, breaking the sales and delivery records for high-end vehicles priced above 400,000 yuan in the Chinese passenger car market. The strong sales momentum of the new ES8 indicates that the golden age of large three-row pure electric SUVs has arrived.
From now until May 31, 2026, car buyers can apply for a 5-year, 60-installment financial plan provided by designated cooperative institutions of NIO, with zero down payment. The annualized interest rate is 0% for the first three years and 3% for the following two years. At the same time, customers who order the new ES8 and successfully lock in their orders can enjoy a limited-time purchase tax subsidy of 10,000 yuan, five years of free use of the full-domain navigation assistance NOP+, and a five-piece set of first-class cabin amenities.
Related Articles

MICROPORT NEURO (02172) spent 986,500 Hong Kong dollars to repurchase 100,000 shares on May 13th.

7ROAD (00797) repurchased 20,000 shares for HK$11,400 on May 13th.

On May 13th, DINGDANG HEALTH (09886) spent 2.9257 million Hong Kong dollars to repurchase 2.887 million shares.
MICROPORT NEURO (02172) spent 986,500 Hong Kong dollars to repurchase 100,000 shares on May 13th.

7ROAD (00797) repurchased 20,000 shares for HK$11,400 on May 13th.

On May 13th, DINGDANG HEALTH (09886) spent 2.9257 million Hong Kong dollars to repurchase 2.887 million shares.

RECOMMEND

Two Mainland Accounting Firms Approved for H‑Share Audits, Lowering Listing Costs and Deepening Mainland–Hong Kong Market Integration**The Ministry of Finance, the CSRC, and Hong Kong’s Accounting and Financial Reporting Council have approved two additional mainland accounting firms—RSM China and ShineWing—to conduct H‑share audit work, marking the first expansion of the list since 2010.
11/05/2026

HKEX Tightens Rules on Auditor Dismissals as Sudden “Audit Firm Switches” Raise Governance Concerns
11/05/2026

The Chip Stock Frenzy Is Still Accelerating
11/05/2026


